rTMS for Apathy Clinical Trial
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: rTMS, methylphenidate.
- Who it may be relevant to
- Registry conditions: Alzheimer Disease, Apathy in Dementia, Dementia, Mild Behavioural Impairment. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Repetitive Transcranial Magnetic Stimulation for Apathy Clinical Trial (REACT)
Overview
Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in neurocognitive disorders and mild behavioural impairment in individuals receiving methylphenidate and individuals not receiving medication for apathy.
Interventions
- Device rTMS
repetitive transcranial magnetic stimulation - Drug methylphenidate
methylphenidate
Primary outcome measures
- Neuropsychiatric Inventory-apathy [Time frame: 2 weeks]
Eligibility criteria
Inclusion criteria
- mild or major neurocognitive disorder OR mild behavioural impairment
- Apathy for at least 4 weeks
- Stable dose of medication (>4 weeks) that may affect cognition or behaviour
- Care partner who spends at least 10 hours a week with the subject
Exclusion criteria
- Current major depressive episode
- Agitation, delusions, hallucination
- Medical contraindications to rTMS
- Currently taking an amphetamine product
- Central nervous system abnormalities, Tourette's syndrome, or motor tics
- Current participation in another clinical trial
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Canada · 1 center
- Sunnybrook Health Sciences Centre — Toronto
Identifiers
NCT: NCT05561205 · SUN-5342